JP2018505218A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505218A5 JP2018505218A5 JP2017560462A JP2017560462A JP2018505218A5 JP 2018505218 A5 JP2018505218 A5 JP 2018505218A5 JP 2017560462 A JP2017560462 A JP 2017560462A JP 2017560462 A JP2017560462 A JP 2017560462A JP 2018505218 A5 JP2018505218 A5 JP 2018505218A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- solvate
- salt
- peritonitis
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 26
- 239000012453 solvate Substances 0.000 claims description 26
- 206010067125 Liver injury Diseases 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 206010034674 peritonitis Diseases 0.000 claims description 18
- 231100000439 acute liver injury Toxicity 0.000 claims description 17
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 15
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 6
- 229960004308 acetylcysteine Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 231100000753 hepatic injury Toxicity 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 239000001530 fumaric acid Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims description 3
- 239000003862 glucocorticoid Substances 0.000 claims description 3
- 229960005489 paracetamol Drugs 0.000 claims description 3
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 108700012359 toxins Proteins 0.000 claims description 3
- 229930186147 Cephalosporin Natural products 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims description 2
- 229940126575 aminoglycoside Drugs 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 229940124587 cephalosporin Drugs 0.000 claims description 2
- 150000001780 cephalosporins Chemical class 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 229940124307 fluoroquinolone Drugs 0.000 claims description 2
- -1 fluoroquinolones Chemical class 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
- 229940041033 macrolides Drugs 0.000 claims description 2
- 150000002960 penicillins Chemical class 0.000 claims description 2
- 229960001476 pentoxifylline Drugs 0.000 claims description 2
- 210000004303 peritoneum Anatomy 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 229940040944 tetracyclines Drugs 0.000 claims description 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 2
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 208000019423 liver disease Diseases 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562114304P | 2015-02-10 | 2015-02-10 | |
| US62/114,304 | 2015-02-10 | ||
| PCT/US2015/051467 WO2016130179A1 (en) | 2015-02-10 | 2015-09-22 | Cenicriviroc for the treatment of fibrosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020042730A Division JP2020111586A (ja) | 2015-02-10 | 2020-03-12 | 線維症の治療用のセニクリビロック |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018505218A JP2018505218A (ja) | 2018-02-22 |
| JP2018505218A5 true JP2018505218A5 (cg-RX-API-DMAC7.html) | 2018-10-25 |
| JP6676660B2 JP6676660B2 (ja) | 2020-04-08 |
Family
ID=56614560
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560462A Expired - Fee Related JP6676660B2 (ja) | 2015-02-10 | 2015-09-22 | 線維症の治療用のセニクリビロック |
| JP2020042730A Pending JP2020111586A (ja) | 2015-02-10 | 2020-03-12 | 線維症の治療用のセニクリビロック |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020042730A Pending JP2020111586A (ja) | 2015-02-10 | 2020-03-12 | 線維症の治療用のセニクリビロック |
Country Status (15)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4316203B2 (ja) | 2001-08-08 | 2009-08-19 | トビラ セラピューティクス インク | 二環性化合物、その製造法および用途 |
| CA2971093A1 (en) | 2014-12-23 | 2016-06-30 | Tobira Therapeutics, Inc. | Process of making cenicriviroc and related analogs |
| MX2018015871A (es) | 2016-06-21 | 2019-08-14 | Tobira Therapeutics Inc | Cenicriviroc purificado e intermedios purificados para fabricar cenicriviroc. |
| WO2022235440A1 (en) * | 2021-04-21 | 2022-11-10 | The United States Government As Represented By The Department Of Veterans Affairs | Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2 |
| CN119954974B (zh) * | 2025-04-09 | 2025-07-22 | 四川康德赛医疗科技有限公司 | 一种工程化巨噬细胞，其制备方法及抗纤维化的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2249027A (en) * | 1990-10-23 | 1992-04-29 | Fujisawa Pharmaceutical Co | Use of macrolide compounds for hepatic failure |
| JP4316203B2 (ja) | 2001-08-08 | 2009-08-19 | トビラ セラピューティクス インク | 二環性化合物、その製造法および用途 |
| WO2006059716A1 (ja) | 2004-12-03 | 2006-06-08 | Takeda Pharmaceutical Company Limited | 固形製剤 |
| US8148356B2 (en) * | 2005-08-24 | 2012-04-03 | Cumberland Pharmaceuticals, Inc. | Acetylcysteine composition and uses therefor |
| ES2636679T3 (es) * | 2011-06-27 | 2017-10-06 | Université Pierre Et Marie Curie (Paris 6) | Péptidos antagonistas de CCR2 |
| JP6263815B2 (ja) * | 2013-03-05 | 2018-01-24 | 国立大学法人 岡山大学 | 細胞死抑制剤及びその製造方法 |
| MY180145A (en) * | 2013-05-15 | 2020-11-23 | Tobira Therapeutics Inc | Cenicriviroc compositions and methods of making and using the same |
| KR101669124B1 (ko) * | 2013-07-11 | 2016-10-25 | 서울대학교병원 | 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물 |
-
2015
- 2015-09-22 CN CN201580076576.9A patent/CN107405403B/zh not_active Expired - Fee Related
- 2015-09-22 WO PCT/US2015/051467 patent/WO2016130179A1/en not_active Ceased
- 2015-09-22 SG SG11201706028RA patent/SG11201706028RA/en unknown
- 2015-09-22 HK HK18106984.5A patent/HK1247558A1/zh unknown
- 2015-09-22 CA CA2975445A patent/CA2975445A1/en not_active Abandoned
- 2015-09-22 US US15/549,958 patent/US20180110754A1/en not_active Abandoned
- 2015-09-22 JP JP2017560462A patent/JP6676660B2/ja not_active Expired - Fee Related
- 2015-09-22 BR BR112017016388-8A patent/BR112017016388A2/pt not_active Application Discontinuation
- 2015-09-22 AU AU2015382376A patent/AU2015382376B2/en not_active Expired - Fee Related
- 2015-09-22 ES ES15882259T patent/ES2864767T3/es active Active
- 2015-09-22 RU RU2017130289A patent/RU2722641C2/ru active
- 2015-09-22 MX MX2017010277A patent/MX2017010277A/es unknown
- 2015-09-22 KR KR1020177023821A patent/KR20170113596A/ko not_active Ceased
- 2015-09-22 EP EP15882259.3A patent/EP3256124B1/en not_active Not-in-force
-
2017
- 2017-07-23 IL IL253617A patent/IL253617A0/en unknown
-
2019
- 2019-02-26 US US16/285,867 patent/US20190343806A1/en not_active Abandoned
-
2020
- 2020-03-12 JP JP2020042730A patent/JP2020111586A/ja active Pending
- 2020-06-03 US US16/891,979 patent/US20200360347A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020111586A5 (cg-RX-API-DMAC7.html) | ||
| JP2018505218A5 (cg-RX-API-DMAC7.html) | ||
| JP2017105763A5 (cg-RX-API-DMAC7.html) | ||
| HRP20250480T1 (hr) | Kombinacija dasatiniba i adagrasiba za primjenu u liječenju nesitnostaničnog raka pluća | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| AR094374A1 (es) | Composiciones y métodos para el tratamiento de trastornos metabólicos | |
| JP2015038135A5 (cg-RX-API-DMAC7.html) | ||
| BR112014027010A2 (pt) | uso de laquinimod de alta dose para tratamento de esclerose múltipla | |
| BR112018012870A2 (pt) | métodos e composições para o tratamento de transtornos relacionados à crise | |
| JP2015537009A5 (cg-RX-API-DMAC7.html) | ||
| JP2015510916A5 (cg-RX-API-DMAC7.html) | ||
| NZ714963A (en) | Compositions and methods for treating anemia | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| JP2017508817A5 (cg-RX-API-DMAC7.html) | ||
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| JP2016510326A5 (cg-RX-API-DMAC7.html) | ||
| JP2016512817A5 (cg-RX-API-DMAC7.html) | ||
| JP2017503014A5 (cg-RX-API-DMAC7.html) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| BRPI0816798A2 (pt) | composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação | |
| HRP20241716T1 (hr) | Postupci liječenja promjena u ponašanju | |
| JP2020529995A5 (cg-RX-API-DMAC7.html) | ||
| RU2017130289A (ru) | Ценикривирок для лечения фиброза | |
| JP2018503685A5 (cg-RX-API-DMAC7.html) |